Bioanalytical and Biomarker Assay Development for COVID-19 Therapeutics and Vaccines

Bioanalytical and Biomarker Assay Development for COVID-19 Therapeutics and Vaccines

Contract Research

Information

All clinical trials for COVID-19 need PCR assays that detect the virus and determine an active infection. Antibody and neutralizing assays are necessary to identify if a therapy or vaccine produces antibodies against the virus. There are also essential biomarkers to measure in COVID-19 trials. Cytokines can be measured in the blood to characterize the cytokine storm that SARS-CoV-2 creates in the lungs. Other functional biomarker assays such as the ELISPOT determine if T cells are helping produce antibodies after vaccination.
CelerionCelerion, a leader in early clinical research services and clinical bioanalysis, is a global company with over 50 years of experience. Our unique combination of medical expertise, clinical operations experience and scientific excellence provides our customers with the guidance to make fast, accurate decisions about their drug development. Celerion has proven experience across a variety of vaccines, including different routes of administration, and patient populations. Our track record spans both preventive and therapeutic vaccines, subunit, and conjugates across all phases I-IV in more than 20 countries, 300 study centers and 4500 subjects.

Log in